Peptide Initiative

Dosing protocol · Healing & Recovery

PACAP-38 dosing & administration

Neuroprotective polypeptide with potent anti-inflammatory and cytoprotective properties discovered in 1989

Suggested dose

10 pmol/kg/min

Once dailyFrequency
Intravenous infusionRoute
Ongoing/indefiniteCycle length

Dosing

How much PACAP-38 do I take?

Intravenous

Intravenous: Delivered straight into a vein through a drip (IV), done by a clinician.

Bioavailability Complete (about 100%) — delivered straight into the bloodstream.

  • 10 pmol/kg/min

    Frequency
    Continuous infusion
    Duration
    20-minute single infusion

    Standardized human experimental-medicine provocation dose; 10 pmol/kg/min over 20 min was selected as the optimal/maximum tolerated rate after dose-finding (5-20 pmol/kg/min) and is reproduced across headache-model trials . Used as a research provocation agent, not an approved therapeutic.

Timing

Best time to take

PACAP-38 is administered intravenously in a clinical setting. Timing is determined by your healthcare provider based on the treatment protocol and your medical needs.

With food?

IV administration of PACAP-38 is not dependent on meal timing. Your healthcare team will provide specific instructions regarding food and fluid intake around treatment sessions.

If stacking

PACAP-38 should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

Adjusting your dose

Increase if

  • You've tolerated the current dose for the recommended period without significant side effects
  • Therapeutic goals haven't been met at the current dose level
  • Your healthcare provider recommends dose escalation based on your response
  • Lab work or clinical assessments support a higher dose

Decrease if

  • Side effects are bothersome or impacting daily life despite management strategies
  • You experience any signs of an adverse reaction
  • Lab results indicate the need for dose reduction
  • Your healthcare provider recommends a lower dose based on your response

Signs of right dose

  • Therapeutic goals being met with minimal side effects
  • Stable and consistent response to treatment
  • Lab values or clinical markers trending in the right direction
  • Good tolerance with manageable or absent side effects

Administration

How do I use PACAP-38?

Reconstitution

What you need

  • PACAP-38 vial (lyophilized powder or solution)
  • Bacteriostatic water or sterile sodium chloride for reconstitution
  • Alcohol swabs for cleaning vial tops and injection sites
  • Appropriately sized syringes with fine-gauge needles (27-30 gauge)
  • Sharps disposal container

Injection

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

Storage

Before reconstitution

Store PACAP-38 in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

After reconstitution

Once reconstituted, PACAP-38 should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs of degradation — discard the vial

  • Solution appears cloudy, discolored, or contains visible particles (should be clear)
  • Product has been exposed to temperatures outside the recommended storage range
  • Product has been frozen (unless specifically designed for freeze-thaw stability)
  • Expiration date has passed or reconstituted solution has exceeded its use-by date
  • Unusual odor, color change, or visible contamination

Sample daily schedule

  • As prescribed (once daily)

    As prescribed by your healthcare provider injection

    Site: Intravenous infusion—rotate sites if applicable

    Maintain a consistent schedule for optimal results with PACAP-38. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.

Safety

Is PACAP-38 safe?

Side effects

Commonly reported: Flushing, Tachycardia, Gastrointestinal Effects, Transient Warmth Sensation

Less common: Headache and Migraine Triggering, Hypotension

Serious side effects

  • Systemic Hypotension and Cardiovascular Effects
  • Systemic Inflammatory Activation

Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with PACAP-38
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

PACAP-38 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

Flagged pairings

  • Triptans — PACAP-38 triggers migraine through cranial vasodilation; triptans target the same trigeminal pathway creating pharmacological conflict
  • Strong Vasodilators — Additive vasodilation through multiple pathways may cause dangerous hypotension
  • PAC1 Receptor Antagonists — Direct pharmacological antagonism blocks PACAP-38 primary neuroprotective mechanism

Published research

What the studies show

  • Strong human trials (Phase 3 or FDA approved)
  • Research compound
  1. More Than Three Decades After Discovery of the Neuroprotective Effect of PACAP, What Is Still Preventing Its Clinical Use?

    Cherait A, et al. · 2025PubMed

    No abstract available for comprehensive analysis.

  2. PACAP38 in human models of primary headaches

    Ashina H, et al. · 2017PubMed

    No abstract available for comprehensive analysis.

  3. Effect of Lu AG09222 on PACAP38-induced vasodilation, heart rate increase, and headache in healthy subjects

    Rasmussen NB, et al. · 2023PubMed

    Lu AG09222, a humanized antibody against PACAP, significantly reduced PACAP38-induced artery dilation and inhibited heart rate increases—demonstrating proof-of-mechanism for migraine prevention. Concomitant headache was reduced.

  4. PACAP glycosides promote cell outgrowth and reduce infarct size after stroke in preclinical model

    Bernard K, et al. · 2024PubMed

    PACAP glycosides retained neurotrophic activity in vitro while improving blood-brain barrier penetration, reducing infarct size by approximately 36% in stroke models. These modified peptides show promise for neuroprotection.

  5. Intranasal PACAP reduces infarct volume and promotes functional recovery after middle cerebral artery occlusion

    Cherait A, et al. · 2020PubMed

    Intranasal PACAP administration proved far more efficient than intravenous injection for reducing infarct volume after middle cerebral artery occlusion. Neuroprotection and functional recovery improved within 6 hours of stroke onset.

  6. The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers

    Birk S, Sitarz JT, Petersen KA, Oturai PS, Kruuse C, Fahrenkrug J, Olesen J · 2007PubMed

  7. Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers

    Amin FM, Asghar MS, Guo S, Hougaard A, Hansen AE, Schytz HW, et al. · 2012PubMed

  8. Hypersensitivity to PACAP-38 in post-traumatic headache: a randomized clinical trial

    Al-Khazali HM, Christensen RH, Dodick DW, et al. · 2024PubMed

Head to head

PACAP-38 compared

Want the full picture?

The complete PACAP-38 research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.